Follow
Peter Bronsert
Peter Bronsert
Institute of Surgical Pathology, University Medical Center, Freiburg, Germany
Verified email at uniklinik-freiburg.de - Homepage
Title
Cited by
Cited by
Year
The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer
AM Krebs, J Mitschke, M Lasierra Losada, O Schmalhofer, M Boerries, ...
Nature cell biology 19 (5), 518-529, 2017
9422017
Pancreatogastrostomy versus pancreatojejunostomy for RECOnstruction after PANCreatoduodenectomy (RECOPANC, DRKS 00000767): perioperative and long-term results of a multicenter …
T Keck, UF Wellner, M Bahra, F Klein, O Sick, M Niedergethmann, ...
Annals of surgery 263 (3), 440-449, 2016
3902016
Cancer cell invasion and EMT marker expression: a three‐dimensional study of the human cancer–host interface
P Bronsert, K Enderle‐Ammour, M Bader, S Timme, M Kuehs, A Csanadi, ...
The Journal of pathology 234 (3), 410-422, 2014
3582014
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in …
J Hoeppner, F Lordick, T Brunner, T Glatz, P Bronsert, N Röthling, ...
BMC cancer 16, 1-10, 2016
3332016
Spatially confined sub-tumor microenvironments in pancreatic cancer
BT Grünwald, A Devisme, G Andrieux, F Vyas, K Aliar, CW McCloskey, ...
Cell 184 (22), 5577-5592. e18, 2021
2752021
Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions
M Schwabenland, H Salié, J Tanevski, S Killmer, MS Lago, AE Schlaak, ...
Immunity 54 (7), 1594-1610. e11, 2021
2642021
ZEB 1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
S Meidhof, S Brabletz, W Lehmann, BT Preca, K Mock, M Ruh, J Schüler, ...
EMBO molecular medicine 7 (6), 831-847, 2015
2392015
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO …
E Fokas, A Schlenska-Lange, B Polat, G Klautke, GG Grabenbauer, ...
JAMA oncology 8 (1), e215445-e215445, 2022
2242022
ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival
SM Gilbert, CJ Oliphant, S Hassan, AL Peille, P Bronsert, S Falzoni, ...
Oncogene 38 (2), 194-208, 2019
1732019
Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate-and high-risk prostate cancer-a …
C Zamboglou, M Carles, T Fechter, S Kiefer, K Reichel, TF Fassbender, ...
Theranostics 9 (9), 2595, 2019
1282019
Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer
E Pérez-Gómez, C Andradas, S Blasco-Benito, MM Caffarel, ...
Journal of the National Cancer Institute 107 (6), djv077, 2015
1242015
SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis
T Boettler, B Csernalabics, H Salié, H Luxenburger, L Wischer, ES Alizei, ...
Journal of Hepatology 77 (3), 653-659, 2022
1232022
A four-chemokine signature is associated with a T-cell–inflamed phenotype in primary and metastatic pancreatic cancer
JM Romero, B Grünwald, GH Jang, PP Bavi, A Jhaveri, M Masoomian, ...
Clinical Cancer Research 26 (8), 1997-2010, 2020
1202020
L1CAM expression in endometrial carcinomas: an ENITEC collaboration study
LJM Van Der Putten, N Visser, K Van de Vijver, M Santacana, P Bronsert, ...
British journal of cancer 115 (6), 716-724, 2016
1112016
Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer
P Bronsert, I Kohler, S Timme, S Kiefer, M Werner, O Schilling, Y Vashist, ...
Surgery 156 (1), 97-108, 2014
1092014
Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist 68Ga-RM2 and PET
C Stoykow, T Erbes, HR Maecke, S Bulla, M Bartholomä, S Mayer, ...
Theranostics 6 (10), 1641, 2016
1082016
Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
B Kulemann, S Rösch, S Seifert, S Timme, P Bronsert, G Seifert, V Martini, ...
Scientific reports 7 (1), 4510, 2017
1022017
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
M Barsch, H Salié, AE Schlaak, Z Zhang, M Hess, LS Mayer, C Tauber, ...
Journal of Hepatology 77 (2), 397-409, 2022
972022
Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary …
P Bronsert, I Kohler, M Werner, F Makowiec, S Kuesters, J Hoeppner, ...
BMC cancer 13, 1-13, 2013
972013
[68Ga-] PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard …
AS Bettermann, C Zamboglou, S Kiefer, CA Jilg, S Spohn, ...
Radiotherapy and Oncology 141, 214-219, 2019
962019
The system can't perform the operation now. Try again later.
Articles 1–20